metricas
covid
Archivos de la Sociedad Española de Oftalmología (English Edition) Acute phase Vogt-Koyanagi-Harada syndrome resistant to corticosteroid therapy in...
Journal Information
Vol. 100. Issue 11.
Pages 723-727 (November 2025)
Vol. 100. Issue 11.
Pages 723-727 (November 2025)
Clinical case
Acute phase Vogt-Koyanagi-Harada syndrome resistant to corticosteroid therapy in an adult female patient
Síndrome de Vogt-Koyanagi-Harada en fase aguda resistente a la terapia con corticosteroides en una paciente adulta
Z.E. Kurt
Corresponding author
drzeyneperdem94@gmail.com

Corresponding author.
, M.A. Argin
Department of Ophthalmology, Faculty of Medicine, Mersin University, Mersin, Turkey
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Abstract

Vogt-Koyanagi-Harada (VKH) syndrome is a rare inflammatory disease that affects more than one system, including ophthalmological, auditory, cutaneous, and neurological systems. VKH syndrome is mostly characterized by panuveitis with serous retinal detachment, headache, hearing loss, vitiligo, and poliosis. Early diagnosis and proper management are crucial to prevent irreversible visual loss and other complications. We present a case report of VKH syndrome in a 29-year-old female patient. Initiation of corticosteroid therapy led to gradual regression of her symptoms. However, after cessation of corticosteroid therapy, the patient’s visual acuity decreased, and the symptoms reappeared. Consequently, combination therapy with corticosteroid, azathioprine, and cyclosporine controlled the disease and stabilized clinical findings.This article highlights that early diagnosis and treatment of VKH syndrome with corticosteroid along with azathioprine and cyclosporine in the acute phase may improve a patient's quality of life and reduce the severity of the disease.

Keywords:
Vogt-Koyanagi-Harada syndrome
Uveitis
Panuveitis
Resumen

El síndrome de Vogt-Koyanagi-Harada (VKH) es una enfermedad inflamatoria rara que afecta a múltiples sistemas, incluyendo los sistemas oftalmológico, auditivo, cutáneo y neurológico. El síndrome de VKH se caracteriza principalmente por panuveítis con desprendimiento de retina seroso, cefalea, pérdida de audición, vitiligo y poliosis. El diagnóstico precoz y el manejo adecuado son cruciales para prevenir la pérdida visual irreversible y otras complicaciones. Presentamos un caso de síndrome de VKH en una paciente femenina de 29 años. El inicio de la terapia con corticosteroides condujo a una regresión gradual de sus síntomas. Sin embargo, después de la suspensión de la terapia con corticosteroides, la agudeza visual de la paciente disminuyó y los síntomas reaparecieron. En consecuencia, la terapia combinada con corticosteroides, azatioprina y ciclosporina controló la enfermedad y estabilizó los hallazgos clínicos. Este artículo destaca que el diagnóstico y tratamiento tempranos del síndrome de VKH con corticosteroides junto con azatioprina y ciclosporina en la fase aguda pueden mejorar la calidad de vida del paciente y reducir la gravedad de la enfermedad.

Palabras clave:
Síndrome de Vogt-Koyanagi-Harada
Uveítis
Panuveítis

Article

These are the options to access the full texts of the publication Archivos de la Sociedad Española de Oftalmología (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Archivos de la Sociedad Española de Oftalmología (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools